Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05845424
Other study ID # DECISION-CALCIUM
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date June 1, 2023
Est. completion date June 30, 2030

Study information

Verified date April 2023
Source Samsung Medical Center
Contact Seung-Hyuk Choi, MD
Phone 82-2-3410-3419
Email sh1214.choi@samsung.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.


Description:

Atherosclerotic cardiovascular diseases (ASCVD), such as myocardial infarction (MI), ischemic stroke, or peripheral arterial disease, are the leading cause of morbidity and mortality worldwide. The causality of low-density lipoproteins cholesterol (LDL-C) level in the development of ASCVD is well demonstrated in previous studies. After introducing LDL-C lowering agents, multiple large-scale randomized clinical trials have demonstrated lower cardiovascular events with lowering LDL-C levels. In particular, for secondary prevention, more aggressive control of LDL-C levels with high-intensity statin therapy significantly reduced cardiovascular events compared with moderate-intensity statin therapy. In addition, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) proved the clinical efficacy of additive ezetimibe for incrementally lowering of LDL-C levels in patients with acute coronary syndrome. However, there has been limited evidence regarding the efficacy and safety of aggressive lipid-lowering strategy using high-intensity statin with a combination of ezetimibe for primary prevention of cardiovascular events among persons without cardiovascular disease. Although the Heart Outcomes Prevention Evaluation (HOPE)-3 and Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trials consistently identified that the use of rosuvastatin (10 mg or 20 mg) was significantly associated with reduced future risk of major cardiovascular events in patients who did not have cardiovascular disease, those studies have been focused on the use of statin, not on the intensity of statin. The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or ASCVD risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD to guide the use of statin or not. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk. Considering that statin has additional properties, including atherosclerotic plaque stabilization, oxidative stress reduction, enhancement of endothelial function, and a decrease in vascular inflammation beyond their lipid-lowering effect, aggressive treatment with a high-intensity statin plus ezetimibe combination might have beneficial effects on the long-term clinical outcomes for asymptomatic patients with significant coronary calcium (Agatston Score ≥ 100) compared with standard lipid-lowering therapy endorsed by the current guidelines. Therefore, the purpose of DECISION-CALCIUM (Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM) trial is to compare the efficacy and safety of the aggressive lipid-lowering therapy with combination of high-intensity statin and ezetimibe, compared with the current standard lipid-lowering therapy in asymptomatic patients with significant coronary calcification for primary prevention.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 6000
Est. completion date June 30, 2030
Est. primary completion date June 30, 2029
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Subject must be at least 40 years of age. - Asymptomatic patients with presence of coronary calcification (Agatston Score = 100) - low-density lipoproteins cholesterol (LDL-C) <190 mg/dL Exclusion Criteria: - Objective evidence of at least moderate inducible ischemia requiring revascularization treatment - History of cerebrovascular disease - History of coronary or peripheral arterial revascularization - Active liver disease or persistent unexplained serum transaminase elevations more than 2 times the upper limit of normal range - History of any adverse drug reaction requiring discontinuation of statin (e, g. rhabdomyolysis) - Allergy or sensitivity to any statin or ezetimibe - Concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine - Pregnancy or breast feeding - Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment) - Unwillingness or inability to comply with the procedures described in this protocol.

Study Design


Intervention

Drug:
Guideline directed statin therapy
At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
High intensity statin plus ezetimibe therapy
Rosuvastatin 20 mg + Ezetimibe 10 mg

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Major adverse cardiovascular events a composite of death from any causes, myocardial infarction, stroke, unplanned coronary revascularization, or other arterial revascularization procedure up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary All-cause death Death from any causes up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Cardiovascular death Death from cardiovascular causes up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Stroke Ischemic or hemorrhagic stroke up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Unplanned coronary revascularization revascularization procedure to coronary artery up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Arterial revascularization procedure All arterial revascularization procedure up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Major bleeding Bleeding Academic Research Consortium (BARC) type 3-5 up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Bleeding BARC type 2-5 up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Heart failure hospitalization Hospitalization due to heart failure up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Coronary calcium progression Delta CAC up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Changes of LDL-C Delta LDL-C up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary New-onset diabetes mellitus Occurence of new-onset diabetes mellitus up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Hepatic disorder requiring discontinuation of statin Occurence of hepatic disorder requiring discontinuation of statin up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary muscle-related adverse events Occurence of muscle-related adverse events due to statin up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Proportion of patients with LDL-C < 100mg/dL Proportion of patients with LDL-C < 100mg/dL up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
Secondary Proportion of patients with LDL-C < 70mg/dL Proportion of patients with LDL-C < 70mg/dL up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A